Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Isabel Kurth, Ph.D.

VP of Research

Isabel received her M.Sc. in Chemistry from the University of Bern, Switzerland, and her Ph.D. from the Institute of Experimental Cancer Research (ISREC), University of Lausanne, Switzerland. Following a brief postdoctoral fellowship at Columbia University, Isabel joined The Rockefeller University to continue her research studies.

As a protein biochemist, her interest has focused on various aspects of cellular proliferation in cancer, bacteria and immunology, with emphasis on DNA replication, DNA repair and telomere biology. She has authored numerous book chapters as well as international reviews and her research discoveries have been published in leading journals including Nature, the EMBO journal, Journal of Experimental Medicine, and Nature Structural Molecular Biology. Isabel is a recipient of the ISREC Ph.D. fellowship and a postdoctoral fellowship from the Swiss National Research Foundation.